In this video Dr. Alyssa Mourning, DVM, gives a thorough overview of FLUTD. Well learn how to recognize the signs of FLUTD, potential diagnostics as well as potential treatments and dietary therapies. This information is not meant to replace the advice of your regular veterinarian.
Genre: Animal Videos
by: VetVid
www.urovirtual.net Prostatic Photo-vaporization with laser Cyber Green performed by Dr. Gilberto Chechile, director of Prostate Institute Barcelona and the Medical Technologic Institute.
Genre: How-to
by: Chechile
R. Kelly does a public service announcement about Urinary Tract Infections
Genre: Funny Videos
by: Brentin777
According to the vet Alera did not suffer from urinary track or constipation. That is good news.
by: ngothyeaun
For all fun loving persons Guess whats coming out of the persons urinary tract?is it urine?is it semen?is it anything else?
Genre: Photos
by: raosaabh
For more info on this and other stories, visit www.newsinfusion.com Corona, CA, January 27, 2009 – Watson Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has approved GELNIQUE™ (oxybutynin chloride) Gel 10%, the first and only topical gel for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency. The U.S. OAB market currently exceeds $1.8 billion annually and continues to grow each year. GELNIQUE will provide OAB patients with an effective and novel alternative to currently available oral treatment options. Because the active ingredient in GELNIQUE is delivered transdermally, it is not metabolized by the liver in the same way as orally administered oxybutynin. This results in a low level of side effects, such as dry mouth and constipation. GELNIQUE will be actively marketed to physicians, and Watson anticipates that the ...
Genre: Entertainment
by: newsinfusion
This video, narrated by This Morning GP Dr Chris Steele, looks into BPH and hears from those who suffer from it. Prostate UK is launching a campaign to raise awareness of benign prostatic hyperplasia (BPH) a non-cancerous enlargement of the prostate gland. BPH affects more than a third of men aged over 50 years, equating to around 3.2 million men in the UK, most of whom suffer in silence. The campaign is being unveiled at a parliamentary reception in the House of Commons, which the charity is hosting with funding from GlaxoSmithKline UK Limited (GSK). The campaign has two key objectives. The first is to encourage men to seek medical advice for unexplained urinary symptoms rather than assuming they are a normal part of ageing. The second is to ensure that where appropriate, BPH is managed by GPs in the primary care setting in order to treat it earlier and minimise costly surgical interventions. This video, narrated by This Morning GP Dr Chris Steele, looks into BPH and hears from those who suffer from it.
Genre: News Videos
by: RadioLynxContent
